A prospective, randomised, controlled, parallel arm, open phase IIa study on the efficacy and safety of the GnRH analogue triptorelin for HIV-1 reservoir reduction in HIV-1 infected male adult patients on suppressive ART
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Triptorelin (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Immune System Regulation
- 27 Mar 2018 New trial record
- 15 Mar 2018 Status changed from planning to recruiting.
- 15 Mar 2018 According to an Immune System Regulation media release, the study comprises 26 + 26 patients from the Huddinge and Sodersjukhuset infection clinics in Stockholm.